Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 9/20 | 0.49 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | MMP13 | P45452 | 2/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6022790 | 1.00 | ADAM17 (0.49) | ADAM17MMP2MMP13MMP12MMP1 | |
| SCHEMBL6022798 | 1.00 | ADAM17 (0.49) | ADAM17MMP2MMP13MMP12MMP1 | |
| SCHEMBL6024016 | 0.92 | ADAM17 (0.47) | ADAM17MMP2MMP13ADAMTS4 | |
| SCHEMBL6024023 | 0.92 | ADAM17 (0.47) | ADAM17MMP2MMP13ADAMTS4 | |
| SCHEMBL6024021 | 0.92 | ADAM17 (0.47) | ADAM17MMP2MMP13ADAMTS4 | |
| SCHEMBL5036449 | 0.84 | ADAM17 (0.48) | ADAM17MMP2MMP13ADAMTS4 | |
| SCHEMBL6023570 | 0.79 | MIF (0.58) | ADAM17MMP13ADAMTS4 | |
| SCHEMBL6024346 | 0.79 | ADAM17 (0.47) | ADAM17MMP2MMP13MMP12MMP1 | |
| SCHEMBL6023102 | 0.78 | ADAM17 (0.49) | ADAM17MMP2MMP13ADAMTS4 | |
| SCHEMBL6023170 | 0.78 | ADAM17 (0.58) | ADAM17ADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7125870-B2 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-24 | — | — | US | disclosed |
| US-20040122005-A1 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-24 | — | — | US | disclosed |
| WO-2004043349-A2 | ISOXAZOLINE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122005-A1 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | MMP2, MMP1, MMP9 | ADAM17 5/4885MMP2 1/4885MMP13 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.